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ApoCIII glycoforms determination and proteomic 
analysis in plasma of coronary patients with different 
ApoCIII levels 
  
BACKGROUND: The aims of this study were:i) to analyze and quantify 
the apolipoproteinCIII glycoforms characterized by none, one or two sialic 
acids,(having different lipoprotein lipase-LPL-inhibitory activity), ii) to 
assess their relationship with  LPL activity and ApoA-V in CAD patients, 
iii) to analyze some previously identified plasma proteins in relation to 
lipids status.   
METHODS: ApoCIII glycoforms in four groups of patients (from “Verona Heart 
Study” biobank,) classified according to the total plasma concentration of ApoCIII 
and different triglyceride (TG) levels, were analyzed by a classical (isoelectric 
focusing/western blotting) and by a shotgun MS approach. LPL activity 
(Fluorescent assay) and ApoA-V concentration (ELISA assay) were determined, 
and their correlations with lipid metabolism parameters were analyzed. 
Tabel 1.  Characteristics of the subjects 
groups Number of 
samples 
ApoCIII 
levels 
Fatty acids profile 
1 7 low (7.25  1.45 mg/dL) A (poly- unsaturated > 40%) 
2 5 low (7.25  1.45 mg/dL)  B (poly- unsaturated < 40%) 
3 7 high (17.31  3.98 mg/dL) A (poly- unsaturated > 40%) 
4 7 high (17.31  3.98 mg/dL) B (poly- unsaturated < 40%) 
Note: The level of apolipoprotein C-III was determined using an 
automated turbidimetric immunoassay; are considered low values ​​<9.2 
mg / dL and higher than ≥ 12.6 mg / dL. The polyunsaturated (PUFA) 
profile has been defined by gas chromatography. 
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Figure1. ApoCIII detection after IEF and diffusion blotting. (A) GROUP 1 low ApoCIII ;(B) GROUP 
2 low ApoCIII; (C) GROUP 3 high ApoCIII;(D) GROUP 4 high ApoCIII 
Variable Concentration Triglycerides ApoCIII 
  
LPL 
(μmol/ml)* 
3,10 
(2,72 -3,53) 
r= 0,034 
p= 0,805 
r= 0,188 
p= 0,165 
r= 0,153 
p= 0,259 
Apo A-V 
ng/ml* 
496,90       
(369,70-667,87) 
r= -0,245 
p= 0,143 
-  - 
Variable  Range (min-max) Normality 
value 
Apo C-III 
(mg/dl) 
11,81 ± 3,84 3,17 - 20,44  < 10.5 
  
LPL 
(μmol/ml)*  
3,10 
 (2,72 -3,53) 
0,78 - 7,21  -  
Apo A-V 
ng/ml*  
496,90  
(369,70 -667,87) 
66 - 2395,95  - 
r = correlation coefficient, p = p-value 
 
Table2. ApoAV and LPL correlations with 
apolipoprotein CIII and triglycerides 
Table 3.Mean values, with standard deviation, 
range and normal values, relative to the 
concentration of apolipoprotein and LPL activity 
RESULTS & DISCUSSION: 
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CONCLUSIONS: As compared with the other ones, mono – sialylated isoform of apo CIII is preferentially associated  with TG  levels. Samples with elevated 
levels of apoCIII are characterized by specific proteomic patterns. 
The distribution of the three ApoCIII glycoforms in the selected 
groups of patients are related to the TG levels, particularly the 
mono-sialylated isoform (ApoCIII-1) prevails in patients 
 with the highest TG levels. 
The mean concentration of ApoAV measured in our study group 
(496.90 ng / ml, CI 369.70 to 667.87), falls within the normal range, 
however upper than prevoiusly reported. LPL activity, measured as 
Vmax, does not show significant correlations with ApoCIII.   
Good agreement between IEF analysis and MS approach in 
terms of abundance % of isoforms. The MS analysis on a new 
set (n=60) of CAD patients is actually ongoing!  
 
Figure2.  (A)workflow MS analysis;(B) Chromatogram of the LC-MS analysis of intact ApoC3 
glycoforms (left-up) and skyline interface for glycoforms quantification (left-down); chromatogram of the 
LC-SWATH-MS analysis of proteomic profile of plasma sample (right-up) and skyline interface protein 
quantification (right-down); 
 
HybridSPE(R)-Phospholipid 
200 µL Human Plasma 
100 L 100 L 
Elution with ACN 
ApoC31/ApoC30 
ApoC32/ApoC30 
SWATH-MS analysis  
proteomic profile 
(digestion) 
MRM-MS analysis 
Intact ApoC3  
Glycoforms 
Quantification of proteins 
(≈ 40 proteins) 
A B 
SWATH-MS 
analysis 
MRM-MS analysis 
Intact ApoC3 glycoforms Proteomic profile 
Figure3.Chromatogram and TOF MS with the ions of the glycoforms Sum of the three most abundant 
ions for +8 and +9 charge state  of each glycoforms for relative quantification 
 
